Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02699450 · ClinicalTrials.gov registry record · Phase 2
A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 229
- Enrollment target
NCT02699450 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 229 participants.
The verdict
NCT02699450, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 229 participants
- Enrollment target
Study Summary
This is a multiple-center, multiple-dose, randomized, active comparator-controlled, double-masked, three parallel group, 36-week study in participants with center-involving diabetic macular edema (DME). Only one eye will be selected as the study eye. Where both eyes meet all eligibility criteria, the eye with the worse best corrected visual acuity (BCVA) will be defined as the study eye. The study will consist of a treatment period (20 weeks) and an observational period (up to 16 weeks). Treatment naive participants will be randomized in a 1:1:1 ratio to one of the Arms A, B and C, respectively. Participants previously treated with intravitreal (IVT) anti-vascular endothelial growth factor (VEGF) will be randomized in a 1:1 ratio to Arms A and C.
Interventions
- DRUG Faricimab
- DRUG Ranibizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 229 participants |
| Start Date | 2016-04-27 |
| Est. Completion | 2017-12-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02699450
The ClinicalTrials.gov registry entry for NCT02699450 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 229 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Faricimab is the first listed.
NCT02699450 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02699450 about?
NCT02699450 is a clinical study titled "A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema". This is a multiple-center, multiple-dose, randomized, active comparator-controlled, double-masked, three parallel group, 36-week study in participants with center-involving diabetic macular edema (DME). Only one eye will be selected as the study eye. Where both eyes meet all eligibility criteria, th...
What is the current status of trial NCT02699450?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 229 participants. The study started on 2016-04-27. Estimated completion is 2017-12-14.
What interventions are being tested in trial NCT02699450?
The interventions under investigation include: Faricimab (DRUG), Ranibizumab (DRUG).
Who is sponsoring clinical trial NCT02699450?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.